20-EPI-VITAMIN-D3 ANALOGS - A NOVEL CLASS OF POTENT REGULATORS OF CELL-GROWTH AND IMMUNE-RESPONSES

被引:309
作者
BINDERUP, L [1 ]
LATINI, S [1 ]
BINDERUP, E [1 ]
BRETTING, C [1 ]
CALVERLEY, M [1 ]
HANSEN, K [1 ]
机构
[1] LEO PHARMACEUT PROD,DEPT CHEM RES,DK-2750 BALLERUP,DENMARK
关键词
D O I
10.1016/0006-2952(91)90426-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The 20-epi-vitamin D3 analogues are a novel class of vitamin D3 derivatives, structurally related to 1-alpha,25-dihydroxycholecalciferol (1-alpha,25(OH)2D3). They are characterized by an altered stereochemistry at carbon 20 in the side-chain. In vitro, these new analogues were found to be considerably more potent as regulators of growth and differentiation in the human histiocytic lymphoma cell line U 937 than 1-alpha,25(OH)2D3, despite a practically unchanged calcemic activity in vivo. The most potent analogue, KH 1060, inhibited cell proliferation by 50% at 10(-12) M (14,000 times more active than 1-alpha,25(OH)2D3). At the same time, KH 1060 induced cell differentiation at concentrations as low as 10(-14) M. In addition, the 20-epi-vitamin D3 analogues were found to be very potent inhibitors of T-lymphocyte proliferation induced by interleukin-1 or alloantigen. In this respect, they were several orders of magnitude more active than the potent immunosuppressive agent cyclosporin A (CyA). KH 1060, the most potent analogue, inhibited interleukin-l-induced mouse thymocyte proliferation by 50% at 3 x 10(-16) M and allogeneic stimulation of mouse spleen lymphocytes at 5 x 10(-15) M. These effects were considered to be mediated by inhibition of interleukin-2 release from activated T-lymphocytes. The new analogues are of potential interest in the prevention of graft rejection and in the treatment of psoriasis, cancer and auto-immune diseases.
引用
收藏
页码:1569 / 1575
页数:7
相关论文
共 37 条
[1]   A SYNTHETIC ANALOG OF VITAMIN-D3, 22-OXA-1-ALPHA,25-DIHYDROXYVITAMIN-D3, IS A POTENT MODULATOR OF INVIVO IMMUNOREGULATING ACTIVITY WITHOUT INDUCING HYPERCALCEMIA IN MICE [J].
ABE, J ;
TAKITA, Y ;
NAKANO, T ;
MIYAURA, C ;
SUDA, T ;
NISHII, Y .
ENDOCRINOLOGY, 1989, 124 (05) :2645-2647
[2]  
AMENTO E P, 1987, Steroids, V49, P55, DOI 10.1016/0039-128X(87)90079-1
[3]   INFLUENCE OF 1,25-HYDROXYVITAMIN-D3 ON CYTOSOLIC FREE CALCIUM CONCENTRATIONS [J].
BAR, S ;
LIDOR, C ;
HARELL, A ;
EDELSTEIN, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 141 (03) :1236-1241
[4]  
BHALLA AK, 1984, J IMMUNOL, V133, P1748
[5]   EFFECTS OF A NOVEL VITAMIN-D ANALOG MC-903 ON CELL-PROLIFERATION AND DIFFERENTIATION INVITRO AND ON CALCIUM-METABOLISM INVIVO [J].
BINDERUP, L ;
BRAMM, E .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (05) :889-895
[6]  
BINDERUP L, 1988, VITAMIN D MOL CELLUL, P300
[7]   SYNTHESIS OF MC-903, A BIOLOGICALLY-ACTIVE VITAMIN-D METABOLITE ANALOG [J].
CALVERLEY, MJ .
TETRAHEDRON, 1987, 43 (20) :4609-4619
[8]   LYMPHOCYTE-T INHIBITION BY CYCLOSPORINE - POTENTIAL MECHANISMS OF ACTION [J].
COLOMBANI, PM ;
HESS, AD .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (22) :3789-3793
[9]  
COLSTON K, 1982, CANCER RES, V42, P856
[10]   ALFACALCIDOL AS A MODULATOR OF GROWTH OF LOW-GRADE NON-HODGKINS LYMPHOMAS [J].
CUNNINGHAM, D ;
GILCHRIST, NL ;
COWAN, RA ;
FORREST, GJ ;
MCARDLE, CS ;
SOUKOP, M .
BRITISH MEDICAL JOURNAL, 1985, 291 (6503) :1153-1155